查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602363

肢端肥大症治疗市场：依疾病类型、药物类别、通路、最终用户划分 - 2025-2030 年全球预测

Acromegaly Treatment Market by Disease Type (Ectopic Acromegaly, Pseudo Acromegaly), Drug Class (Bromocriptine Mesylate (Parlodel), Dopamine Agonists, Growth Hormone Receptor Antagonist), Distribution Channel, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年肢端肥大症治疗市值为24.8亿美元，预计2024年将达27.2亿美元，复合年增长率为9.92%，预计到2030年将达到48.1亿美元。

肢端肥大症是一种罕见的荷尔蒙失调，其特征是生长激素分泌过多，通常由脑下垂体良性肿瘤引起。肢端肥大症的治疗包括药物、手术和放射线治疗，旨在降低生长激素水平并缓解症状。肢端肥大症治疗的市场需求凸显，因为这种疾病如果不及时治疗可能会导致严重的健康併发症，因此早期诊断和介入至关重要。应用主要是内分泌诊所和专业医疗机构，由于疾病的慢性性质，最终用途主要用于药物干预。

主要市场统计
基准年[2023] 24.8亿美元
预测年份 [2024] 27.2亿美元
预测年份 [2030] 48.1亿美元
复合年增长率（%） 9.92%

推动市场成长的关键因素包括对罕见荷尔蒙疾病的认识不断提高、诊断技术的进步以及新型药物治疗的开拓。生技药品和胜肽製剂的技术创新以及外科技术的突破带来了巨大的商机。随着微创治疗方法的引入和药物传输系统的改进，市场环境可能会进一步加强。然而，高昂的治疗成本、由于罕见疾病而导致的患者数量有限以及当前治疗方法的潜在副作用等挑战是市场扩张的障碍。此外，监管障碍和漫长的核准流程可能会减缓新治疗方法的推出。

利用成长机会的研究包括投资研发以创造更有效、侵入性更小的治疗方法，以及扩展到意识和诊断率不断提高的新兴市场。生物技术公司与医学研究机构之间的合作加速了创新。创新和研究的最佳领域包括开发个人化医疗方法以及探索细胞疗法和基因编辑技术，以从根本上解决肢端肥大症。市场动态是动态的、创新主导的，需要专注于前沿研究和策略伙伴关係关係，以克服复杂性并充分发挥潜力。

市场动态：快速发展的肢端肥大症治疗市场的关键市场洞察

肢端肥大症治疗市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 世界各地遗传和荷尔蒙疾病的流行
    • 提高对肢端肥大症诊断与治疗的认识
    • 采用外科手术及放射线治疗治疗肢端肥大症
  • 市场限制因素
    • 肢端肥大症治疗高成本且发生药品召回
  • 市场机会
    • 肢端肥大症新药物製剂及给药途径的开发
    • 核准荷尔蒙疗法治疗肢端肥大症
  • 市场挑战
    • 与药物治疗相关的副作用

波特五力：驾驭肢端肥大症治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解肢端肥大症治疗市场的外在影响

外部宏观环境因素在塑造肢端肥大症治疗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解肢端肥大症治疗市场的竞争状况

对肢端肥大症治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵肢端肥大症治疗市场供应商的表现评估

FPNV定位矩阵是评估肢端肥大症治疗市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製肢端肥大症治疗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，肢端肥大症治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 遗传和荷尔蒙疾病的全球盛行率
      • 提高对肢端肥大症诊断与治疗的认识
      • 采用手术和放射线治疗治疗肢端肥大症
    • 抑制因素
      • 肢端肥大症治疗费用高且药品回收发生率高
    • 机会
      • 肢端肥大症新药物製剂及给药途径的开发
      • 核准荷尔蒙疗法治疗肢端肥大症
    • 任务
      • 与药物治疗相关的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章肢端肥大症治疗市场：依疾病类型

  • 异位肢端肥大症
  • 假性肢端肥大症

第七章肢端肥大症治疗市场（依药物类别）

  • 甲磺酸溴隐亭（Parlodel）
  • 多巴胺促效剂
  • 生长激素受体拮抗剂
  • 生长抑制素类似物 (SSA)
  • Somatuline Depot（Lanreotide）
  • 索玛巴特（培维索孟）

第八章肢端肥大症治疗市场：依通路

  • 医院药房
  • 网路药房
  • 零售药房

第九章肢端肥大症治疗市场：依最终用户分类

  • 门诊手术中心
  • 家庭护理设置
  • 医院/诊所

第10章美洲肢端肥大症治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太肢端肥大症治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲肢端肥大症治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Advanz Pharma Services（UK）Limited
  • Aetna Inc.
  • Amolyt Pharma SAS
  • Amryt Pharma PLC
  • Bayer AG
  • Biodexa Pharmaceuticals PLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Crinetics Pharmaceuticals, Inc.
  • DexTech Medical AB
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Foresee Pharmaceuticals Co., Ltd.
  • Hikma Pharmaceuticals PLC
  • Ionis Pharmaceuticals, Inc.
  • Ipsen Pharma
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Peptron Inc.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Validus Pharmaceuticals LLC
  • Xeris Pharmaceuticals, Inc.
Product Code: MRR-742BD517A3A4

The Acromegaly Treatment Market was valued at USD 2.48 billion in 2023, expected to reach USD 2.72 billion in 2024, and is projected to grow at a CAGR of 9.92%, to USD 4.81 billion by 2030.

Acromegaly is a rare hormonal disorder characterized by the excessive production of growth hormone, typically caused by benign tumors on the pituitary gland. The treatment landscape for acromegaly includes medications, surgical procedures, and radiation therapies designed to reduce growth hormone levels and mitigate symptoms. Market necessity for acromegaly treatments is underscored by the condition's potential to cause serious health complications if left unmanaged, making early diagnosis and intervention crucial. The application is primarily in endocrine clinics and specialized healthcare facilities, with pharmaceutical interventions being the primary end-use focus due to the chronic nature of the condition.

KEY MARKET STATISTICS
Base Year [2023] USD 2.48 billion
Estimated Year [2024] USD 2.72 billion
Forecast Year [2030] USD 4.81 billion
CAGR (%) 9.92%

Key factors driving market growth include rising awareness of rare hormonal disorders, advancements in diagnostic technologies, and the development of novel pharmacological treatments. Innovations in biologics and peptide-based formulations, as well as breakthroughs in surgical techniques, present significant opportunities. The introduction of less invasive treatment options and improved drug delivery systems could further enhance the market landscape. However, challenges such as high treatment costs, limited patient populations due to the rarity of the disease, and potential side effects of current therapies pose barriers to market expansion. Additionally, regulatory hurdles and lengthy approval processes can delay the introduction of new treatments.

Recommendations for leveraging growth opportunities include investing in research and development to create more effective, less invasive treatments and expanding into emerging markets where awareness and diagnosis rates are increasing. Collaborations between biotech firms and medical research institutions can accelerate innovation. Best areas of innovation and research include developing personalized medicine approaches and exploring cell therapy or gene editing technologies to address acromegaly at its root. The acromegaly treatment market is dynamic and innovation-driven, necessitating a focus on cutting-edge research and strategic partnerships to navigate its complexities and realize its potential fully.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Acromegaly Treatment Market

The Acromegaly Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of genetic & hormonal diseases worldwide
    • Rising awareness regarding acromegaly diagnosis & treatment
    • Adoption of surgical procedures and radiation therapies for acromegaly treatment
  • Market Restraints
    • High cost of acromegaly treatment and incidences of drug recalls
  • Market Opportunities
    • Development of new acromegaly drug formulations and route of administration
    • Hormone therapy approvals for acromegaly treatments
  • Market Challenges
    • Side effects associated with drug treatments

Porter's Five Forces: A Strategic Tool for Navigating the Acromegaly Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Acromegaly Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Acromegaly Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Acromegaly Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Acromegaly Treatment Market

A detailed market share analysis in the Acromegaly Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Acromegaly Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Acromegaly Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Acromegaly Treatment Market

A strategic analysis of the Acromegaly Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Acromegaly Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Advanz Pharma Services (UK) Limited, Aetna Inc., Amolyt Pharma SAS, Amryt Pharma PLC, Bayer AG, Biodexa Pharmaceuticals PLC, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Crinetics Pharmaceuticals, Inc., DexTech Medical AB, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Foresee Pharmaceuticals Co., Ltd., Hikma Pharmaceuticals PLC, Ionis Pharmaceuticals, Inc., Ipsen Pharma, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Mylan N.V., Novartis AG, Peptron Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Validus Pharmaceuticals LLC, and Xeris Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Acromegaly Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Ectopic Acromegaly and Pseudo Acromegaly.
  • Based on Drug Class, market is studied across Bromocriptine Mesylate (Parlodel), Dopamine Agonists, Growth Hormone Receptor Antagonist, Somatostatin Analogs (SSAs), Somatuline Depot (Lanreotide), and Somavert (Pegvisomant).
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Homecare Settings, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of genetic & hormonal diseases worldwide
      • 5.1.1.2. Rising awareness regarding acromegaly diagnosis & treatment
      • 5.1.1.3. Adoption of surgical procedures and radiation therapies for acromegaly treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of acromegaly treatment and incidences of drug recalls
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of new acromegaly drug formulations and route of administration
      • 5.1.3.2. Hormone therapy approvals for acromegaly treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with drug treatments
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Acromegaly Treatment Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Ectopic Acromegaly
  • 6.3. Pseudo Acromegaly

7. Acromegaly Treatment Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Bromocriptine Mesylate (Parlodel)
  • 7.3. Dopamine Agonists
  • 7.4. Growth Hormone Receptor Antagonist
  • 7.5. Somatostatin Analogs (SSAs)
  • 7.6. Somatuline Depot (Lanreotide)
  • 7.7. Somavert (Pegvisomant)

8. Acromegaly Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Acromegaly Treatment Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Homecare Settings
  • 9.4. Hospitals & Clinics

10. Americas Acromegaly Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Acromegaly Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Acromegaly Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Advanz Pharma Services (UK) Limited
  • 3. Aetna Inc.
  • 4. Amolyt Pharma SAS
  • 5. Amryt Pharma PLC
  • 6. Bayer AG
  • 7. Biodexa Pharmaceuticals PLC
  • 8. Boehringer Ingelheim International GmbH
  • 9. Bristol-Myers Squibb Company
  • 10. Crinetics Pharmaceuticals, Inc.
  • 11. DexTech Medical AB
  • 12. Dr. Reddy's Laboratories Ltd.
  • 13. Eli Lilly and Company
  • 14. Foresee Pharmaceuticals Co., Ltd.
  • 15. Hikma Pharmaceuticals PLC
  • 16. Ionis Pharmaceuticals, Inc.
  • 17. Ipsen Pharma
  • 18. Lupin Pharmaceuticals, Inc.
  • 19. Merck & Co., Inc.
  • 20. Mylan N.V.
  • 21. Novartis AG
  • 22. Peptron Inc.
  • 23. Pfizer Inc.
  • 24. Teva Pharmaceutical Industries Ltd.
  • 25. Validus Pharmaceuticals LLC
  • 26. Xeris Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. ACROMEGALY TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. ACROMEGALY TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ACROMEGALY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ACROMEGALY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ACROMEGALY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ACROMEGALY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ACROMEGALY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ACROMEGALY TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY ECTOPIC ACROMEGALY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY PSEUDO ACROMEGALY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY BROMOCRIPTINE MESYLATE (PARLODEL), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY DOPAMINE AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY GROWTH HORMONE RECEPTOR ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY SOMATOSTATIN ANALOGS (SSAS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY SOMATULINE DEPOT (LANREOTIDE), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY SOMAVERT (PEGVISOMANT), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ACROMEGALY TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ACROMEGALY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ACROMEGALY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ACROMEGALY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM ACROMEGALY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM ACROMEGALY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM ACROMEGALY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. ACROMEGALY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. ACROMEGALY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023